Celcuity reports Phase 1b/2 mCRPC trial data at ESMO 2026
Tweet Send to a Friend
Celcuity Inc. (Nasdaq: CELC) presented updated clinical data from a Phase 1b/2 study evaluating gedatolisib combined with darolutamide in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




